




Product Specification Sheet

Product Name:	MLN-8237 (Alisertib)
Catalog Number:	C6561-2 (powder) C6561-2s (10mM in DMSO)
Package Size:	2 mg
Technical information:	
Chemical Formula:	C ₂₇ H ₂₀ ClFN ₄ O ₄
CAS #:	1028486-01-2
Molecular Weight:	518.92
Purity:	>98%
Formulation:	White solid
Solubility:	Soluble in DMSO up to 50 mM
Chemical Name:	4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid
Storage:	Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.
Handling:	<ul style="list-style-type: none">For C6561-2 (powder), add 386 µL of DMSO to make 10 mM solution.For C6561-2s, before open the vial, centrifuge the vial at 500rpm x 1 min in a 50 mL conical tube to ensure full sample recovery.
Biological Activity:	MLN-8237 is a second-generation, selective Aurora A kinase (AAK) inhibitor with an IC ₅₀ of 1 nM. MLN8237 shows 200-fold more selective activity against Aurora-A than related kinase Aurora-B. Inhibition of AAK by MLN-8237 induces cytotoxicity and cell arrest. Several completed as well as actively on-going phase I/II clinical trials evaluate MLN-8237 in advanced solid tumor as well as advanced hematological malignancies.
Reference:	<ol style="list-style-type: none">Gorgun G et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010; 115(25): 5202–5213.Manfredi MG et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011; 17(24):7614-24.



For Technical Support: technical@cellagentech.com

For research use only, not for clinical or diagnostic use.